Skip to main content

Coronavirus (COVID-19): Visitor Restrictions, Resources, and Updates

Explore URMC
menu
URMC / Research / Clinical Trials / Study Details

Study of Testosterone and rHGH in FSHD

Basic Study Information

Purpose:
The purpose of this study is to investigate the safety and tolerability of combination therapy with recombinant human growth hormone (rHGH) and testosterone in adult male patients with facioscapulohumeral muscular dystrophy (FSHD) over 24 weeks.

Location: University of Rochester

Lead Researcher (Principal Investigator)

Lead Researcher: Elizabeth Luebbe

Study Contact Information

Study Coordinator: Chad Heatwole, MD
Phone: 585-275-7867
Email: elizabeth_luebbe@urmc.rochester.edu

Additional Study Details

Contact This Study

This field is required
This field is required
You must agree to be contacted to continue.

Return to Search